1-n-hexylaminomethyl-1,1-bisphosphonic acid | 32545-69-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物
• 英文名称: 1-n-hexylaminomethyl-1,1-bisphosphonic acid
• 英文别名: 1-n-Hexylamino-methan-1,1-diphosphonsaeure；[(Hexylamino)-phosphonomethyl]phosphonic acid
• CAS: 32545-69-0
• 化学式: C₇H₁₉NO₆P₂
• 分子量: 275.178
• InChiKey: UXLZYKHQCOQILT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.5
• 重原子数：
  16
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  127
• 氢给体数：
  5
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  tetraethyl 1-n-hexylaminomethyl-1,1-bisphosphonate 在 盐酸 作用下， 以 水 为溶剂， 反应 24.0h， 以81%的产率得到1-n-hexylaminomethyl-1,1-bisphosphonic acid
  参考文献：
  名称：

  1-烷基氨基甲基-1,1-双膦酸的合成及其对克鲁氏锥虫和弓形虫的生物学评价。

  摘要：

  作为我们旨在寻找针对南美锥虫病和弓形虫病的新型化学治疗剂的项目的扩展，分别设计，合成了几种1,1-双膦酸酯，并分别针对这些疾病的病原体克氏锥虫和弓形体弓形虫进行了生物学评估。特别地，并且基于针对法呢基二磷酸合酶的2-烷基氨基乙基-1,1-双膦酸酯表现出的抗寄生虫活性，一系列的线性2-烷基氨基甲基-1,1-双膦酸（化合物21-33），即氨基的位置是一个更靠近宝石膦酸酯部分的碳原子，被评估为对克氏锥虫临床上更相关的分裂形式（amastigotes）的生长抑制剂。尽管所有这些化合物都没有抗寄生虫活性，这些结果对于严格的SAR研究是有价值的。另外，出乎意料的是，合成设计的2-环烷基氨基乙基-1，1-双膦酸47-49没有抗寄生虫活性。此外，长链含硫的1，1-双膦酸，例如化合物54-56、59，被证明是刚地弓形虫速殖子的纳摩尔生长抑制剂。由于许多含双膦酸酯的分子是FDA批准的用于治疗骨吸收疾病的药物，

  DOI：

  10.1016/j.bmc.2019.07.004

文献信息

• Effects of Bisphosphonates on the Growth of <i>Entamoeba histolytica</i> and <i>Plasmodium </i>Species in Vitro and in Vivo
  作者：Subhash Ghosh、Julian M. W. Chan、Christopher R. Lea、Gary A. Meints、Jared C. Lewis、Zev S. Tovian、Ryan M. Flessner、Timothy C. Loftus、Iris Bruchhaus、Howard Kendrick、Simon L. Croft、Robert G. Kemp、Seiki Kobayashi、Tomoyoshi Nozaki、Eric Oldfield

  DOI：10.1021/jm030084x

  日期：2004.1.1

  The effects of a series of 102 bisphosphonates on the inhibition of growth of Entamoeba histolytica and Plasmodium falciparum in vitro have been determined, and selected compounds were further investigated for their in vivo activity. Forty-seven compounds tested were active (IC50 < 200 muM) versus E. histolytica growth in vitro. The most active compounds (IC50 similar to 4-9 muM) were nitrogen-containing bisphosphonates with relatively large aromatic side chains. Simple n-alkyl-1-hydroxy-1,1-bisphosphonates, known inhibitors of the enzyme farnesylpyrophosphate (FPP) synthase, were also active, with optimal activity being found with C9-C10 side chains. However, numerous other nitrogen-containing bisphosphonates known to be potent FPP synthase inhibitors, such as risedronate or pamidronate, had little or no activity. Several pyridine-derived bisphosphonates were quite active (IC50 similar to 10-20 muM), and this activity was shown to correlate with the basicity of the aromatic group, with activity decreasing with increasing pK(a) values. The activities of all compounds were tested versus a human nasopharyngeal carcinoma (KB) cell line to enable an estimate of the therapeutic index (TI). Five bisphosphonates were selected and then screened for their ability to delay the development of amebic liver abscess formation in an E. histolytica infected hamster model. Two compounds were found to decrease liver abscess formation at 10 mg/kg ip with little or no effect on normal liver mass. With P. falciparum, 35 compounds had IC50 values <200 muM in an in vitro assay. The most active compounds were also simple n-alkyl-1-hydroxy-1,1-bisphosphonates, having IC50 values around 1 muM. Five compounds were again selected for in vivo investigation in a Plasmodium berghei ANKA BALB/c mouse suppressive test. The most active compound, a C9 n-alkyl side chain containing bisphosphonate, caused an 80% reduction in parasitemia with no overt toxicity. Taken together, these results show that bisphosphonates appear to be useful lead compounds for the development of novel antiamebic and antimalarial drugs.
• US3957160A
  申请人：——

  公开号：US3957160A

  公开（公告）日：1976-05-18
• US3979385A
  申请人：——

  公开号：US3979385A

  公开（公告）日：1976-09-07